Mhealth market to see strong revenue growth through 2017, study finds
BERLIN — The global market for mobile health app services is expected to reach $26 billion by 2017 as smartphone applications allow the mhealth industry to successfully monetize its services, according to a new report.
Global Mobile Health Market Report 2013-2017, announced Friday by Berlin-based mobile market research firm Research2guidance, found that top mhealth publishers manage to generate more than 3 million free and 300,000 paid downloads in the United States on the Apple iOS platform.
"Our findings indicate that the long-expected mobile revolution in healthcare is set to happen," Research2guidance head of research Ralf-Gordon Jahns said. "Both healthcare providers and consumers are embracing smartphones as a means to improve healthcare."
The study found that in addition to use of mhealth applications by consumers, 15% of them are primarily designed for healthcare professionals, including continuing education, remote monitoring and healthcare management applications. There are currently 97,000 mhealth applications in major app stores, with 42% of them being based on paid business models.
"With the growing level of mhealth applications, only 9% of the total market revenue in the next five years will come from application download revenue," Research2guidance analyst Patrick Houck said. "Eighty-four percent of total mhealth application market revenue will come from related services and products such as sensors."
Multiple cost-management programs can reduce specialty drug spending, report finds
WASHINGTON — Employers that use multiple cost-management programs have a 50% lower specialty drug trend than those that don’t use them, according to a new study by pharmacy benefit manager Express Scripts.
The study, presented Thursday at the National Business Group on Health’s Business Health Agenda 2013 conference in Washington, was described as one of the first to examine the effect of multiple utilization management programs on the cost of specialty medications, which is expected to account for $1 out of every $4 spent on prescription drugs by 2014.
Researchers at the PBM analyzed the specialty drug spending of 60 employer clients who were members of the NBGH, representing more than 5 million Americans with pharmacy benefits; employers were categorized according to the type of cost-management programs they adopted, including unmanaged, somewhat managed and tightly managed. Unmanaged programs included those in which employers’ health plan members could obtain their specialty drugs from any pharmacy; in somewhat managed programs, members used a specialty pharmacy exclusively and one specialty utilization management program; and in tightly managed programs, members used a specialty pharmacy exclusively, combined with multiple specialty utilization management programs.
Employers classified as unmanaged experienced an annual average increase in specialty drug spending per member per year of 27.8%, while those that were tightly managed saw an increase of 13.6%. Overall, according to Express Scripts’ "2012 Drug Trend Report," the increase in spending on specialty drugs was 18.4% last year, compared with 17.1% in 2011. Meanwhile, spending on traditional drugs decreased for the first time, by 1.5%, mostly due to generics.
"Specialty drug costs and use have escalated without sufficient oversight to manage waste or misuse of these expensive medications," Express Scripts SVP clinical research and new solutions Glen Stettin said. "Add in the impact of bad health decisions, and you get both poor financial and clinical outcomes. This data clearly demonstrates that multiple progressive management solutions mitigate the rising cost of specialty therapies by identifying and seizing cost-saving opportunities, as well as enabling better decisions that can lead to improved health outcomes."
Price inflation, increasing utilization and new drug introductions are among the many factors that contribute to the rising costs of specialty medications for hard-to-treat diseases like cancer, hepatitis C and multiple sclerosis, and these medications can cost up to $100,000 per person per year, according to the study.
Medications for inflammatory conditions, multiple sclerosis, cancer and HIV accounted for nearly 70% of annual spending on specialty drugs, according to Express Scripts.
Rite Aid comps decrease 3.6% as same-store prescription count increases 0.3%
CAMP HILL, Pa. — Rite Aid’s same-store sales for February 2013 decreased by 3.6% over the previous year, including a 1.3% decrease in front-end same-store sales and a 4.7% decrease in pharmacy same-store sales, the retail pharmacy chain said Thursday.
Front-end comps attributable to flu-related OTC products were flat, while pharmacy comps included a negative effect of 695 basis points from new generic introductions. Same-store prescription count increased 0.3%, including a 0.1% decrease attributable to flu shots and prescription flu drugs.
Total sales for the 4,623-store chain were $2.457 billion, a 3.7% decrease from last February’s $2.551 billion.
For the 13 weeks ended Saturday, comps were 2% lower, including a 0.3% decrease in front-end comps and a 3.1% decrease in pharmacy comps; same-store prescription count increased by 3%. Total sales decreased by 2.4%, to $6.425 billion. The chain said this was its ninth consecutive quarter of increases in prescription count and 10th consecutive quarter of improved or flat front-end comps.
For the 52 weeks that ended Saturday, comps decreased by 0.3%, including a 1.4% increase in front-end comps and a 1% decrease in pharmacy comps. Total sales for the period were $25.284 billion, a 0.9% decrease from the same period last year.